Home
Conditions
Diabetes Mellitus, Type 2

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

2,679 public trials 155 recruiting studies

Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: Phoenix, Arizona, United States

Concord, California, United States

Greenbrae, California, United States

Los Angeles, California, United States

View all 78 locations

View Trial Details

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

NCT00138554

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: Novartis Pharmaceuticals East Hanover, New Jersey, United States

View Trial Details

Completed

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

NCT01562561

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Shatin, New Territories, Hong Kong

Novo Nordisk Investigational Site Kota Bharu, Kelantan, Malaysia

Novo Nordisk Investigational Site Marikina City, Philippines

Novo Nordisk Investigational Site Pasig, Philippines

View Trial Details

Completed

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

NCT01720290

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Beijing, China

Novo Nordisk Investigational Site Shanghai, China

View Trial Details

Completed

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

NCT00568074

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Shanghai, Shanghai Municipality, China

Novo Nordisk Investigational Site Shanghai, Shanghai Municipality, China

Novo Nordisk Investigational Site Chengdu, Sichuan, China

Novo Nordisk Investigational Site Beijing, China

View Trial Details

Completed

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

NCT01720303

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Shanghai, Shanghai Municipality, China

Novo Nordisk Investigational Site Shanghai, Shanghai Municipality, China

View Trial Details

Completed

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

NCT01698931

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Padova, Italy

View Trial Details

Completed

Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

NCT01465152

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Barcelona, Spain

Novo Nordisk Investigational Site Benamargosa, Spain

Novo Nordisk Investigational Site Burlata, Spain

Novo Nordisk Investigational Site Camas, Spain

View all 18 locations

View Trial Details

Completed

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

NCT00568984

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Tianjin, Tianjin Municipality, China

View all 15 locations

View Trial Details

Completed

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations: Novo Nordisk Investigational Site Houston, Texas, United States

View Trial Details

Diabetes Mellitus, Type 2

Diabetes Mellitus, Type 2 trial results

Related conditions